Back to search

Article

Transposon Mutagenesis Reveals RBMS3 as a Promoter of Malignant Progression of BRAF <sup>V600E</sup> -Driven Lung Tumorigenesis

2022-02-28

Abstract excerpt

<h4>ABSTRACT</h4> Mutationally-activated BRAF V600E is detected in ~2% of all human non-small cell lung cancers (NSCLC), and serves as a predictive biomarker for treatment of patients with FDA-approved pathway-targeted therapies that inhibit signaling by the BRAF V600E oncoprotein kinase. In genetically engineered mouse (GEM) models, expression of BRAF V600E in alveolar type 2 (AT2) pneumocytes initiates the d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3f2880f0-6f31-5ae5-b959-aa94745b0402
DOI
10.1101/2022.02.28.482366
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Transposon Mutagenesis Reveals RBMS3 as a Promoter of Malignant Progression of BRAF <sup>V600E</sup> -Driven Lung TumorigenesisDOI 10.1101/2022.02.28.482366
Select a neighboring publication to make it the new centre.